Trial Profile
A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in HIV-uninfected Adults at Low Risk of HIV Infection
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs ALVAC HIV vCP2438 (Primary) ; MF 59
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 06 Mar 2024 Results assessing safety and immunogenicity of month 30 boost of ALVAC+gp120/MF59 vaccines, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results assessing effects of the 12-month booster on peak post-boost and memory vaccine-induced immune responses, presented at the 9th International AIDS Society Conference on HIV Science.